ID	Title	Short name	Biological organization3	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells	Cellular8	Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity	Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity	Cellular9	Activation, 5HT2c	Activation, 5HT2c	Molecular10	Accumulation, Acetylcholine in synapses	Accumulation, Acetylcholine in synapses	Cellular12	Inhibition, Acetylcholinesterase (AchE)	Inhibition, Acetylcholinesterase (AchE)	Cellular17	Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways	Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways	Molecular18	Activation, AhR	Activation, AhR	Molecular21	Altered regulation, Alpha hemoglobin	Altered regulation, Alpha hemoglobin	Cellular25	Agonism, Androgen receptor	Agonism, Androgen receptor	Molecular26	Antagonism, Androgen receptor	Antagonism, Androgen receptor	Molecular27	N/A, Androgen receptor, Antagonism	N/A, Androgen receptor, Antagonism	Molecular28	Reduction, Angiogenesis	Reduction, Angiogenesis	Molecular29	Reduction in, Angiogenic sprouts	Reduction in, Angiogenic sprouts	35	Decrease, Aromatase (Cyp19a1)	Decrease, Aromatase (Cyp19a1)	Cellular36	Inhibition, Aromatase	Inhibition, Aromatase	Molecular39	Induction, Ataxia, paralysis, or hyperactivity	Induction, Ataxia, paralysis, or hyperactivity	Organ40	Decrease, Mitochondrial ATP production	Decrease, Mitochondrial ATP production	Cellular41	Inhibition, Bile Salt Export Pump (ABCB11)	Inhibition, Bile Salt Export Pump (ABCB11)	Molecular42	Up Regulation, Biliary excretion	Up Regulation, Biliary excretion	46	Accumulation, Biological membranes	Accumulation, Biological membranes	Cellular49	Reduction, Ca and HCO3 transport to shell gland	Reduction, Ca and HCO3 transport to shell gland	Tissue50	Increase, Ca++ (intracellular)	Increase, Ca++ (intracellular)	Cellular51	Inhibition, Ca++ ATPase	Inhibition, Ca++ ATPase	Molecular52	Decreased, Calcium influx	Decreased, Calcium influx	Cellular54	Up Regulation, CD36	Up Regulation, CD36	Molecular55	N/A, Cell injury/death	N/A, Cell injury/death	Cellular57	Proliferation, Cell proliferation in the absence of cytotoxicity	Proliferation, Cell proliferation in the absence of cytotoxicity	Cellular59	Inhibition of Apoptosis in Altered Hepatic Foci, Changes in Cellular Growth Homeostasis	Inhibition of Apoptosis in Altered Hepatic Foci, Changes in Cellular Growth Homeostasis	60	Induction, Chitin degradation and resorption	Induction, Chitin degradation and resorption	62	Induction, Chitin synthesis	Induction, Chitin synthesis	64	Reduction, Ionotropic GABA receptor chloride channel conductance	Reduction, Ionotropic GABA receptor chloride channel conductance	Cellular66	Activation, ChREBP	Activation, ChREBP	Molecular68	Accumulation, Collagen	Accumulation, Collagen	Tissue71	Activation, Constitutive androstane receptor, NR1l3	Activation, Constitutive androstane receptor, NR1l3	75	N/A, Covalent binding to protein, possibly lysine residue	N/A, Covalent binding to protein, possibly lysine residue	Molecular77	Production, Critical Metabolites (CGA 330050 and CGA 265307)	Production, Critical Metabolites (CGA 330050 and CGA 265307)	Cellular78	Reduction, Cumulative fecundity and spawning	Reduction, Cumulative fecundity and spawning	Individual79	Inhibition, Cyclooxygenase activity	Inhibition, Cyclooxygenase activity	Molecular80	Up Regulation, CYP1A1	Up Regulation, CYP1A1	Molecular84	Up Regulation, CYP1B1	Up Regulation, CYP1B1	Molecular87	Release, Cytokine	Release, Cytokine	Cellular89	Synthesis, De Novo FA	Synthesis, De Novo FA	Cellular97	Alkylation, DNA	Alkylation, DNA	Molecular103	Activation, Ecdysone receptor	Activation, EcR	Molecular105	Inhibition, ECT complexes of the respiratory chain	Inhibition, ECT complexes of the respiratory chain	106	Reduction, Eggshell thickness	Reduction, Eggshell thickness	Tissue110	Impairment, Endothelial network	Impairment, Endothelial network	Molecular111	Agonism, Estrogen receptor	Agonism, Estrogen receptor	Molecular112	Antagonism, Estrogen receptor	Antagonism, Estrogen receptor	Molecular115	Increase, FA Influx	Increase, FA Influx	Cellular116	Activation, FAS	Activation, FAS	Molecular118	Formation, Formation of hemoglobin adducts	Formation, Formation of hemoglobin adducts	Cellular119	N/A, Gap	N/A, Gap	Tissue122	Activation, Glucocorticoid Receptor	Activation, Glucocorticoid Receptor	Molecular129	Reduction, Gonadotropins, circulating concentrations	Reduction, Gonadotropins, circulating concentrations	Organ130	Depletion, GSH	Depletion, GSH	Cellular131	Down Regulation, Gulcose-6-phosphate dehydrogenase	Down Regulation, Gulcose-6-phosphate dehydrogenase	Cellular134	Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)	Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)	Cellular135	Increase, Hepatic transport of parent T4	Increase, Hepatic transport of parent T4	136	Up Regulation, Hepatic transporter gene expression	Up Regulation, Hepatic transporter gene expression	139	N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects	N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects	Tissue140	Decreased, HSD17B10 expression	Decreased, HSD17B10 expression	Cellular142	Hyperplasia, Hyperplasia	Hyperplasia, Hyperplasia	Tissue145	Induction, IKB inhibitory protein	Induction, IKB inhibitory protein	Cellular147	Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307	Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307	Cellular149	Increase, Inflammation	Increase, Inflammation	Cellular151	Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways	Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways	Molecular152	Suppression, Inflammatory cytokines	Suppression, Inflammatory cytokines	Individual155	N/A, Insufficient or incorrect DNA repair	N/A, Insufficient or incorrect DNA repair	Cellular158	N/A, Interferences with SH-/selen-proteins	N/A, Interferences with SH-/selen-proteins	Cellular161	Increase, Liver and splenic hemosiderosis	Increase, Liver and splenic hemosiderosis	Organ164	Induction, Liver “Dysfunctional” Changes by CGA 330050	Induction, Liver “Dysfunctional” Changes by CGA 330050	Organ165	Activation, Long term AHR receptor driven direct and indirect gene expression changes	Activation, Long term AHR receptor driven direct and indirect gene expression changes	Cellular166	Decreased, Long-term potentiation (LTP)	Decreased, Long-term potentiation (LTP)	Organ167	Activation, LXR	Activation, LXR	Molecular168	Decreased, Lymphocytes	Decreased, Lymphocytes	Individual169	Disruption, Membrane integrity	Disruption, Membrane integrity	Cellular173	N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number	N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number	Organ176	Damaging, Mitochondria	Damaging, Mitochondria	Cellular177	N/A, Mitochondrial dysfunction 1	N/A, Mitochondrial dysfunction 1	Cellular178	Disruption, Mitochondrial electron transport chain	Disruption, Mitochondrial electron transport chain	Cellular179	Decreased, Mitochondrial fatty acid beta-oxidation	Decreased, Mitochondrial fatty acid beta-oxidation	Molecular183	Abnormal, Morphogenesis	Abnormal, Morphogenesis	185	Increase, Mutations	Increase, Mutations	Molecular186	Altered, Neuroanatomy	Altered, Neuroanatomy	Organ188	N/A, Neuroinflammation	N/A, Neuroinflammation	Tissue191	N/A, Neuronal dysfunction	N/A, Neuronal dysfunction	Cellular192	Altered, Neurophysiology	Altered, Neurophysiology	Organ193	Decreased, Nitric Oxide	Decreased, Nitric Oxide	Cellular195	Inhibition, NMDARs	Inhibition, NMDARs	Molecular201	Binding of antagonist, NMDA receptors	Binding of antagonist, NMDA receptors	Molecular202	Inhibition, Nuclear factor kappa B (NF-kB)	Inhibition, Nuclear factor kappa B (NF-kB)	Molecular209	Peptide Oxidation	Peptide Oxidation	Molecular210	N/A, Oxidative stress	N/A, Oxidative stress	Cellular211	Propagation, Oxidative stress	Propagation, Oxidative stress	Molecular213	N/A, Parent compound is converted to the reactive metabolite and forms free radicals leading to oxidation of heme iron(II) in hemoglobin to iron(III)	N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin	Molecular214	Bile accumulation, Pathological condition	Bile accumulation, Pathological condition	Cellular216	Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)	Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)	Cellular219	Reduction, Plasma 17beta-estradiol concentrations	Reduction, Plasma 17beta-estradiol concentrations	Individual220	Increase, Plasma vitellogenin concentrations	Increase, Plasma vitellogenin concentrations	Organ221	Reduction, Plasma vitellogenin concentrations	Reduction, Plasma vitellogenin concentrations	Organ222	Elimination of (high doses), Posterior cardinal vein	Elimination of (high doses), Posterior cardinal vein	227	Activation, PPAR_	Activation, PPAR_	Molecular228	peroxisome proliferator activated receptor promoter demethylation	demethylation, PPARg promoter	Molecular231	Decreased, PPAR-alpha activation	Decreased, PPAR-alpha activation	Molecular232	Decreased, PPAR-beta activation	Decreased, PPAR-beta activation	Molecular233	Decreased, PPAR-gamma activation	Decreased, PPAR-gamma activation	Molecular234	Activation, PPAR_ & PPAR_	Activation, PPAR_ & PPAR_	Molecular238	Induction, Pre-mature molting	Induction, Pre-mature molting	239	Activation, Pregnane-X receptor, NR1l2	Activation, Pregnane-X receptor, NR1l2	Molecular240	Feminisation or incomplete development, Primary and accessory male sex organs	Feminisation or incomplete development, Primary and accessory male sex organs	Organ243	Reduction, Prostaglandin E2 concentration	Reduction, Prostaglandin E2 concentration	Tissue244	Alkylation, Protein	Alkylation, Protein	Molecular245	Activation, PXR/SXR	Activation, PXR/SXR	Molecular246	Increase, RBC congestion in liver	Increase, RBC congestion in liver	Organ249	Production, Reactive oxygen species	Production, Reactive oxygen species	Tissue250	"Damaging, Red blood cells; hemolysis"	"Damaging, Red blood cells; hemolysis"	Cellular252	Increase, Renal pathology due to VTG deposition	Increase, Renal pathology due to VTG deposition	Organ253	N/A, Reproductive failure	N/A, Reproductive failure	Individual257	Increase, Reactive oxygen species production	Increase, ROS production	Molecular258	Activation, SCD-1	Activation, SCD-1	Molecular259	Decrease, Serum thyroxine (T4)	Decrease, Serum thyroxine (T4)	261	Binding, SH-/selen-proteins	Binding, SH-/selen-proteins	Molecular264	Activation, SREBP-1c	Activation, SREBP-1c	Molecular265	Activation, Stellate cells	Activation, Stellate cells	Cellular266	Decrease, Steroidogenic acute regulatory protein (STAR)	Decrease, Steroidogenic acute regulatory protein (STAR)	Cellular267	Damage, Structure of the cochlea	Damage, Structure of the cochlea	269	Induction, Sustained Cell Proliferation	Induction, Sustained Cell Proliferation	Cellular270	Induction, Sustained Hepatotoxicity	Induction, Sustained Hepatotoxicity	Individual272	Activation/Proliferation, T-cells	Activation/Proliferation, T-cells	Organ274	Reduction, Testosterone synthesis by ovarian theca cells	Reduction, Testosterone synthesis by ovarian theca cells	Cellular276	Up Regulation, TGFbeta1 expression	Up Regulation, TGFbeta1 expression	Cellular277	Decrease of thyroid hormone synthesis	TH synthesis, Decreased	Cellular279	Thyroperoxidase, Inhibition	Thyroperoxidase, Inhibition	Molecular280	Decrease of thyroxine (T4) in neuronal tissue	T4 in neuronal tissue, Decreased	Organ281	Decrease of thyroxine (T4) in serum	T4 in serum, Decreased	Tissue283	Decrease, Tissue thyroid hormone concentration	Decrease, Tissue thyroid hormone concentration	284	Decrease, TR-regulated cochlear proteins	Decrease, TR-regulated cochlear proteins	285	Reduction, Vitellogenin synthesis in liver	Reduction, Vitellogenin synthesis in liver	Tissue286	Decreased, Transcription of genes by AR	Decreased, Transcription of genes by AR	Cellular288	Activation of specific nuclear receptors, Transcriptional change	Activation of specific nuclear receptors, Transcriptional change	Cellular289	Decrease, Translocator protein (TSPO)	Decrease, Translocator protein (TSPO)	Cellular291	Accumulation, Triglyceride	Accumulation, Triglyceride	Cellular294	N/A, Unknown	N/A, Unknown	Molecular295	Induction, Upregulation of glucuronyltransferase activity	Induction, Upregulation of glucuronyltransferase activity	Molecular298	Insufficiency, Vascular	Insufficiency, Vascular	Molecular301	Binding, VEGF-A	Binding, VEGF-A	302	Production, VEGF-A	Production, VEGF-A	304	Decreased, VegfR2	Decreased, VegfR2	305	Inhibition, VegfR2	Inhibition, VegfR2	Molecular307	Increase, Vitellogenin synthesis in liver	Increase, Vitellogenin synthesis in liver	Tissue309	Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development	Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development	Cellular310	Alteration, Wnt pathway	Alteration, Wnt pathway	Cellular312	N/A, Allergic contact dermatitis on challenge	N/A, Allergic contact dermatitis on challenge	Individual313	Increase, Allergic Respiratory Hypersensitivity Response	Increase, Allergic Respiratory Hypersensitivity Response	Organ315	Decreased, Body length	Decreased, Body length	317	Altered, Cardiovascular development/function	Altered, Cardiovascular development/function	Organ319	Loss, Cochlear function	Loss, Cochlear function	Organ320	Increase, Curved body axis	Increase, Curved body axis	321	N/A, Cyanosis occurs	N/A, Cyanosis occurs	Individual323	Increased, Disease susceptibility	Increased, Disease susceptibility	Individual325	N/A, Embryotoxicity	N/A, Embryotoxicity	Individual327	Accumulation, Fatty acid	Accumulation, Fatty acid	Organ328	Reduction, Fecundity	Reduction, Fecundity	330	Decrease, Fertility	Decrease, Fertility	Individual331	Decreased, Fetal birth weight	Decreased, Fetal birth weight	332	Increased, Functional deficits	Increased, Functional deficits	334	Promotion, Hepatocelluar carcinoma	Promotion, Hepatocelluar carcinoma	Individual336	Increase, Heritable mutations in offspring	Increase, Heritable mutations in offspring	Individual337	N/A, Impairment of reproductive capacity	N/A, Impairment of reproductive capacity	Individual339	Altered, Larval development	Altered, Larval development	Individual341	Impairment, Learning and memory	Impairment, Learning and memory	Individual342	Increased, Lethality	Increased, Lethality	344	N/A, Liver fibrosis	N/A, Liver fibrosis	Organ345	N/A, Liver Steatosis	N/A, Liver Steatosis	Organ346	Undefined, Liver Steatosis	Undefined, Liver Steatosis	Organ347	Formation, Liver tumor	Formation, Liver tumor	Individual348	Malformation, Male reproductive tract	Malformation, Male reproductive tract	Organ350	Increase, Mortality	Increase, Mortality	Individual351	Increased, Mortality	Increased, Mortality	Population352	N/A, Neurodegeneration	N/A, Neurodegeneration	Tissue356	Increased, Oxidative damage	Increased, Oxidative damage	Individual357	Cholestasis, Pathology	Cholestasis, Pathology	Individual358	Increase, Pericardial edema	Increase, Pericardial edema	Organ360	Decrease, Population trajectory	Decrease, Population trajectory	Individual361	Decline, Population	Decline, Population	Population363	Altered, Reproductive behaviour	Altered, Reproductive behaviour	Individual364	Impaired development of, Reproductive organs	Impaired development of, Reproductive organs	Individual366	Increased, Structural malformations	Increased, Structural malformations	369	Uroporphyria	Uroporphyria	Individual373	Formation, Pro-mutagenic DNA Adducts	Formation, Pro-mutagenic DNA Adducts	Molecular376	Increased, Induced Mutations in Critical Genes	Increased, Induced Mutations in Critical Genes	Cellular377	Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered Hepatic Foci (AHF))	Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H	378	Tumorigenesis, Hepatocellular carcinoma	Tumorigenesis, Hepatocellular carcinoma	Individual380	Activation, Pre-MIE: Metabolism of AFB1	Activation, Pre-MIE: Metabolism of AFB1	Molecular381	Reduced levels of BDNF	BDNF, Reduced	Molecular382	Aberrant, Dendritic morphology	Aberrant, Dendritic morphology	Cellular383	Reduced, Presynaptic release of glutamate	Reduced, Presynaptic release of glutamate	Molecular384	Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci	Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci	385	Decrease of synaptogenesis	Synaptogenesis, Decreased	Cellular386	Decrease of neuronal network function	Neuronal network function, Decreased	Organ387	Binding of agonist, NMDARs	Binding of agonist, NMDARs	Molecular388	Overactivation, NMDARs	Overactivation, NMDARs	Molecular389	Increased, Intracellular Calcium overload	Increased, Intracellular Calcium overload	Cellular396	Covalent Binding, Protein	Covalent Binding, Protein	Molecular397	Response, Keratinocytes	Response, Keratinocytes	Cellular398	Activation, Dendritic Cells	Activation, Dendritic Cells	Cellular401	Increase, Biliary excretion TH glucuronide	Increase, Biliary excretion TH glucuronide	Organ402	Cognitive Function, Decreased 	Cognitive Function, Decreased	Individual403	Suppression, Immune system	Suppression, Immune system	Individual405	irregularities, ovarian cycle	irregularities, ovarian cycle	Individual406	impaired, Fertility	impaired, Fertility	Individual408	reduction in ovarian granulosa cells, Aromatase (Cyp19a1)	reduction in ovarian granulosa cells, Aromatase (Cyp19a1)	Cellular409	Metabolism of AFB1, Production of Reactive Electrophiles	Metabolism of AFB1, Production of Reactive Electrophiles	Molecular413	Reduction, Testosterone synthesis in Leydig cells	Reduction, Testosterone synthesis in Leydig cells	Cellular414	Increase, Luteinizing hormone (LH) 	Increase, Luteinizing hormone (LH)	Cellular415	Hyperplasia, Leydig cell	Hyperplasia, Leydig cell	Organ416	Increase proliferation, Leydig cell 	Increase proliferation, Leydig cell	Cellular417	skewed, sex ratio	skewed, sex ratio	Population418	Increased, Vitellogenin synthesis	Increased, Vitellogenin synthesis	Cellular419	Increased, renal vitellogenin deposition	Increased, renal vitellogenin deposition	Organ421	Increased, glomerular rupture and renal hemorrhaging	Increased, glomerular rupture and renal hemorrhaging	Organ422	Increased, nephropathy	Increased, nephropathy	Individual423	Increased, Clonal Expansion / Cell Proliferation to Form Pre-Neoplastic Altered Hepatic Foci	Increased, Clonal Expansion / Cell Proliferation to Form Pre-Neoplastic Altered Hepatic Foc	424	Inhibition, Na+/I- symporter (NIS)	Inhibition, Na+/I- symporter (NIS)	Molecular425	Decrease of Thyroidal iodide	Thyroidal Iodide, Decreased	Cellular426	Decreased, Thyroxine (T4) in serum	Decreased, Thyroxine (T4) in serum	Tissue427	Down Regulation, K-Cl co-transporter 2 (KCC2) 	Down Regulation, K-Cl co-transporter 2 (KCC2)	Cellular428	Delay, Developmental GABA shift 	Delay, Developmental GABA shift	Cellular429	Cellular Proliferation and Clonal Expansion of Mutant Cells (Pre-neoplastic Foci), Alteration of cellular growth homeostasis	Cellular Proliferation and Clonal Expansion of Mutant Cells (Pre-neoplastic Foci), Alterati	442	Decreased, Population trajectory	Decreased, Population trajectory	Population444	Increased, Atrioventricular block and bradycardia	Increased, Atrioventricular block and bradycardia	Organ445	Increased, Respiratory distress/arrest	Increased, Respiratory distress/arrest	Organ446	Reduction, testosterone level	Reduction, testosterone level	Tissue447	Reduction, Cholesterol transport in mitochondria	Reduction, Cholesterol transport in mitochondria	Cellular450	Suppression, VLDL secretion	Suppression, VLDL secretion	Cellular451	Inhibition, Mitochondrial fatty acid beta-oxidation	Inhibition, Mitochondrial fatty acid beta-oxidation	Molecular454	Increased, Triglyceride formation	Increased, Triglyceride formation	Cellular455	Accumulation, Liver lipid	Accumulation, Liver lipid	Organ456	Suppression, Constitutive androstane receptor, NR1l3	Suppression, Constitutive androstane receptor, NR1l3	Molecular457	Activation, SREBF1	Activation, SREBF1	Molecular458	Increased, De Novo FA synthesis	Increased, De Novo FA synthesis	Cellular459	Increased, Liver Steatosis	Increased, Liver Steatosis	Organ460	Increased, Fatty acid uptake	Increased, Fatty acid uptake	Cellular461	Suppression, HNF4alpha	Suppression, HNF4alpha	Molecular462	Up Regulation, SCD-1	Up Regulation, SCD-1	Molecular463	Up Regulation, FAS	Up Regulation, FAS	Molecular464	Increased, SCD-1	Increased, SCD-1	Molecular465	Increased, FA Influx	Increased, FA Influx	Cellular466	Up Regulation, LDLR (low density lipoprotein receptor)	Up Regulation, LDLR (low density lipoprotein receptor)	Molecular467	Increased, LDL uptake	Increased, LDL uptake	Cellular468	Inhibition, PPAR alpha	Inhibition, PPAR alpha	Molecular470	Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)	Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)	Molecular471	Inhibition, FoxA2	Inhibition, FoxA2	Molecular472	Down Regulation, CPT1A	Down Regulation, CPT1A	Molecular474	Down Regulation, HMGCS2	Down Regulation, HMGCS2	Molecular475	Increased, Hepatic Triglycerides	Increased, Hepatic Triglycerides	Tissue476	Accumulation, Hepatic FA	Accumulation, Hepatic FA	Organ477	Decreased, Ketogenesis	Decreased, Ketogenesis	Cellular478	Activation, NRF2	Activation, NRF2	Molecular479	Activation, NR1H4	Activation, NR1H4	Molecular480	Activation, SHP	Activation, SHP	Molecular482	Decreased, DHB4/HSD17B4	Decreased, DHB4/HSD17B4	Molecular483	Activation, LXR alpha	Activation, LXR alpha	Molecular484	Activation, AKT2	Activation, AKT2	Molecular485	Activtation, SREBP-1c	Activtation, SREBP-1c	Molecular486	systemic inflammation leading to hepatic steatosis	inflammation	Organ488	Decrease, Ovulation	Decrease, Ovulation	Organ491	Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)	Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)	Organ493	Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts	Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts	Molecular494	Glucocorticoid Receptor Agonist, Activation	GR Agonist, Activation	Molecular495	Repressed expression of steroidogenic enzymes 	Repressed expression of steroidogenic enzymes	Cellular496	Increased apoptosis, decreased number of adult Leydig Cells 	Increased apoptosis, decreased Leydig Cells	Cellular505	Decreased sperm quantity / quality in the adult, Decreased fertility 	Decreased sperm quantity / quality in the adult, Decreased fertility	Individual520	Decreased sperm quantity or quality in the adult, Decreased fertility 	Decreased sperm quantity or quality in the adult, Decreased fertility	Individual525	Apoptosis of adult Leydig cells, Decreased testosterone by adult Leydig cells	Apoptosis of adult Leydig cells, Decreased testosterone by adult Leydig cells	Cellular526	Inhibition, Inhibition of Dopamine-beta-hydroxylase	Inhibition, Inhibition of Dopamine-beta-hydroxylase	Molecular527	Decreased, Decreased fecundity 	Decreased, Decreased fecundity	Individual528	Decreased, Synthesis of NE	Decreased, Synthesis of NE	Cellular529	Decreased, GnRH cfos activity	Decreased, GnRH cfos activity	Molecular530	Decreased, GnRH pulsatility/release	Decreased, GnRH pulsatility/release	Cellular531	Decreased, LH Surge	Decreased, LH Surge	Cellular532	Delayed, Ovulation	Delayed, Ovulation	Individual533	Decreased, Cortical granule release/distribution upon fertilization	Decreased, Cortical granule release/distribution upon fertilization	Cellular534	Altered, Formation of cortical envelope	Altered, Formation of cortical envelope	Cellular535	Abnormal, Sperm penetration (polyspermy)	Abnormal, Sperm penetration (polyspermy)	Cellular536	Altered, Chromosome number (polyploid) zygote	Altered, Chromosome number (polyploid) zygote	Cellular540	Decreased testosterone by the fetal Leydig cells, Dysgensis of fetal Leydig cells	Decreased testosterone by the fetal Leydig cells, Dysgensis of fetal Leydig cells	Organ541	Decreased testosterone by the fetal Leydig cells, Decreased COUP-TFII stem Leydig cells	Decreased testosterone by the fetal Leydig cells, Decreased COUP-TFII stem Leydig cells	Cellular543	Decreased fertility in the adult, Decreased sperm quantity and/or quality in the adult testis	Decreased fertility in the adult, Decreased sperm quantity and/or quality in the adult test	Individual559	Activation, Nicotinic acetylcholine receptor	Activation, Nicotinic acetylcholine receptor	Molecular560	Abnormal, Foraging activity and behavior	Abnormal, Foraging activity and behavior	Individual561	Reduced, Food storage	Reduced, Food storage	Population563	Death/Failure, Colony	Death/Failure, Colony	Population564	Abnormal, Roll change within caste	Abnormal, Roll change within caste	Population565	Reduced, Brood care	Reduced, Brood care	Population566	impaired, Larval development	impaired, Larval development	Population568	impaired, Hive thermoregulation	impaired, Hive thermoregulation	Population570	Accumulation, Damaged mitochondrial DNA	Accumulation, Damaged mitochondrial DNA	Cellular571	Accelerated, Aging	Accelerated, Aging	Individual572	Decrease, Number of worker bees	Decrease, Number of worker bees	Population573	Increase, Energetic demands and therefore metabolic stress	Increase, Energetic demands and therefore metabolic stress	Individual574	Increased, Appetite and hunger	Increased, Appetite and hunger	Individual576	Increased, Viral susceptibility	Increased, Viral susceptibility	Individual577	impaired, Development	impaired, Development	Individual578	Decreased, Glucose oxidase enzyme activity	Decreased, Glucose oxidase enzyme activity	Molecular579	Decreased, Hydrogen peroxide production	Decreased, Hydrogen peroxide production	Molecular580	Reduced, Antiseptic incorporated in food	Reduced, Antiseptic incorporated in food	Population583	impaired, Thoracic shivering	impaired, Thoracic shivering	Individual584	Inhibition, sodium channel	Inhibition, sodium channel	Molecular585	Decreased, Sodium conductance 1	Decreased, Sodium conductance 1	Cellular586	Reduced, swimming speed	Reduced, swimming speed	Individual587	Reduced, feeding 1	Reduced, feeding 1	Individual588	Increased, predation	Increased, predation	Population590	N/A, hypoxia	N/A, hypoxia	Tissue591	Increased, amputations	Increased, amputations	Individual592	Reduced, survival	Reduced, survival	Population593	Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel 	Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel	Molecular598	modulation, sodium channel	modulation, sodium channel	Molecular599	prolonged, Depolarization of neuronal membrane	prolonged, Depolarization of neuronal membrane	Cellular600	Overactivation, Neuronotransmitter release	Overactivation, Neuronotransmitter release	Molecular601	Overactivation, muscle contraction	Overactivation, muscle contraction	Tissue602	Increased, Ataxia, paralysis, or hyperactivity	Increased, Ataxia, paralysis, or hyperactivity	Organ613	Occurrence, Epileptic seizure	Occurrence, Epileptic seizure	Individual616	Occurrence, A paroxysmal depolarizing shift	Occurrence, A paroxysmal depolarizing shift	Tissue618	Decreased, Neuronal network function in adult brain	Decreased, Neuronal network function in adult brain	Organ619	"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"	"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"	Molecular620	Increased, serotonin (5-HT) 1 1	Increased, serotonin (5-HT) 1	Molecular621	Increase, cilia movement	Increase, cilia movement	Tissue622	Increased, locomotion	Increased, locomotion	Individual623	Increase, predation	Increase, predation	Population624	Increased, foot detachment	Increased, foot detachment	Individual625	Increased, muscular waves in foot	Increased, muscular waves in foot	Organ626	Increased, serotonin (5-HT) 	Increased, serotonin (5-HT)	Cellular627	Decreased, anxiety	Decreased, anxiety	Individual629	Decreased, sheltering	Decreased, sheltering	Individual633	Decrease, histaminergic neuron excitation	Decrease, histaminergic neuron excitation	Cellular634	N/A, sedation	N/A, sedation	Individual635	Decreased, locomotion	Decreased, locomotion	Individual636	Decreased, survival	Decreased, survival	Population637	impaired, Learning and memory	impaired, Learning and memory	Individual638	Antagonism, Histamine Receptor (H2)	Antagonism, Histamine Receptor (H2)	Molecular640	Decreased steroidogenesis, Proteomic alterations in the adult Leydig cell	Decreased steroidogenesis, Proteomic alterations in the adult Leydig cell	Molecular642	Decreased Cholesterol, Decreased De Novo Biosynthesis of Choleseterol	Decreased Cholesterol, Decreased De Novo Biosynthesis of Choleseterol	Molecular643	Decreased Cholesterol, Decreased Uptake of Lipoproteins	Decreased Cholesterol, Decreased Uptake of Lipoproteins	Molecular644	Decreased Cholesterol, Decreased Transport of Cholesterol to the Inner Mitochondrial Membrane	Decreased Cholesterol, Decreased Transport of Cholesterol to the Inner Mitochondrial Membra	Molecular645	Decreased Cholesterol, Decreased Testosterone Production by Adult Leydig Cells	Decreased Cholesterol, Decreased Testosterone Production by Adult Leydig Cells	Cellular646	Decreased Cholesterol, Decreased sperm quantity and/or quality in the adult testis	Decreased Cholesterol, Decreased sperm quantity and/or quality in the adult testis	Organ647	Decreased steroidogenesis, Decreased Activity of Steroidogenic Enzymes in Adult Leydig cells	Decreased steroidogenesis, Decreased Activity of Steroidogenic Enzymes in Adult Leydig cell	Cellular648	Decreased steroidogenesis, Increased Apoptosis of Adult Leydig Cells	Decreased steroidogenesis, Increased Apoptosis of Adult Leydig Cells	Tissue649	Decreased steroidogenesis, Alterations in the Leydig Cell Cytoskeleton	Decreased steroidogenesis, Alterations in the Leydig Cell Cytoskeleton	Tissue650	Stimulation of adult Leydig cells via the Adrenal Corticosterone, Increased Glucocorticoid	Stimulation of adult Leydig cells via the Adrenal Corticosterone, Increased Glucocorticoid	Molecular651	Glucocorticoid Receptor mediated alterations in steriodogenic enzymes, Decreased testosterone by adult Leydig cells	Glucocorticoid Receptor mediated alterations in steriodogenic enzymes, Decreased testostero	Cellular652	Direct effects of Corticosterone on steroidogenesis, Decreased testosterone by adult Leydig cells	Direct effects of Corticosterone on steroidogenesis, Decreased testosterone by adult Leydig	Cellular653	Decreased testosterone by the fetal Leydig cells, Increased corticosterone	Decreased testosterone by the fetal Leydig cells, Increased corticosterone	Cellular654	Decreased testosterone by the fetal Leydig cells, Activation by other glucocorticoid receptor agonists	Decreased testosterone by the fetal Leydig cells, Activation by other glucocorticoid recept	Cellular655	Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells	Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells	Cellular656	Decreased number and function of adult Leydig cells, Decreased COUP-TFII stem Leydig cells	Decreased number and function of adult Leydig cells, Decreased COUP-TFII stem Leydig cells	Cellular657	Decreased testosterone by the fetal Leydig cells, Dysgenesis of fetal Leydig cells	Decreased testosterone by the fetal Leydig cells, Dysgenesis of fetal Leydig cells	Organ658	Decreased testosterone by the fetal Leydig cells, Increased estradiol	Decreased testosterone by the fetal Leydig cells, Increased estradiol	Cellular659	Decreased testosterone by the fetal Leydig cells, Activation by other estradiol agonists	Decreased testosterone by the fetal Leydig cells, Activation by other estradiol agonists	Cellular660	decreased testosterone by fetal Leydig cells, Dysgenesis of fetal Leydig cells	decreased testosterone by fetal Leydig cells, Dysgenesis of fetal Leydig cells	Organ661	Decreased testosterone by the fetal Leydig cells, Alterations in the fetal testis proteome	Decreased testosterone by the fetal Leydig cells, Alterations in the fetal testis proteome	Molecular662	Decreased testosterone by the fetal Leydig cells, Hypermethylation in the fetal testis	Decreased testosterone by the fetal Leydig cells, Hypermethylation in the fetal testis	Molecular663	Desensitization, Nicotinic acetylcholine receptor	Desensitization, Nicotinic acetylcholine receptor	Molecular664	Overwhelmed, Mitochondrial DNA repair mechanisms	Overwhelmed, Mitochondrial DNA repair mechanisms	Cellular667	Binding at picrotoxin site, iGABAR chloride channel	Binding at picrotoxin site, iGABAR chloride channel	Molecular669	Reduction, Neuronal synaptic inhibition	Reduction, Neuronal synaptic inhibition	Cellular671	Reduced, Prostaglandin F2alpha concentration, plasma 	Reduced, Prostaglandin F2alpha concentration, plasma	Individual672	Reduced, Prostaglandin F2alpha synthesis, ovary 	Reduced, Prostaglandin F2alpha synthesis, ovary	Organ673	Reduced, Spawning behavior	Reduced, Spawning behavior	Individual674	Reduced, Ability to attract spawning mates	Reduced, Ability to attract spawning mates	Individual675	Reduced, Reproductive Success	Reduced, Reproductive Success	Individual678	Reduced, Pheromone release	Reduced, Pheromone release	Individual679	Decline, Population trajectory	Decline, Population trajectory	Population681	Decreased, Prostaglandin F2alpha synthesis, ovary 	Decreased, Prostaglandin F2alpha synthesis, ovary	Organ682	Generation, Amplified excitatory postsynaptic potential (EPSP)	Generation, Amplified excitatory postsynaptic potential (EPSP)	Cellular685	Reduced, Prostaglandins, ovary	Reduced, Prostaglandins, ovary	Organ686	Declining, Population trajectory	Declining, Population trajectory	Population687	Reduced, Prostaglandin E2 concentration, hypothalamus	Reduced, Prostaglandin E2 concentration, hypothalamus	Tissue689	Reduced, Gonadotropin releasing hormone, hypothalamus	Reduced, Gonadotropin releasing hormone, hypothalamus	Tissue690	Reduced, Luteinizing hormone (LH), plasma 	Reduced, Luteinizing hormone (LH), plasma	Tissue691	Reduced, Maturation inducing steroid, plasma	Reduced, Maturation inducing steroid, plasma	Tissue692	Reduced, Maturation inducing steroid receptor signalling, oocyte	Reduced, Maturation inducing steroid receptor signalling, oocyte	Tissue693	Increased, cyclic adenosine monophosphate	Increased, cyclic adenosine monophosphate	Tissue694	Reduced, Meiotic prophase I/metaphase I transition, oocyte	Reduced, Meiotic prophase I/metaphase I transition, oocyte	Cellular695	Upregulated, Spindle assembly checkpoint protein Mad2-oocyte	Upregulated, Spindle assembly checkpoint protein Mad2-oocyte	Molecular696	Increased, Chromosome misseggregation	Increased, Chromosome misseggregation	Cellular697	impaired, ion channels	impaired, ion channels	Cellular698	Altered, Action Potential	Altered, Action Potential	Cellular699	Increased, cardiac arrthymia	Increased, cardiac arrthymia	Organ708	Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium)	Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium)	Tissue709	Increase, Cytotoxicity (renal tubular cell)	Increase, Cytotoxicity (renal tubular cell)	Cellular710	Increase, Regenerative cell proliferation (tubular epithelial cells)	Increase, Regenerative cell proliferation (tubular epithelial cells)	Cellular713	Increase, Adenomas/carcinomas (renal tubular)	Increase, Adenomas/carcinomas (renal tubular)	Tissue714	Increased, Binding of chemicals to 2u (serum)	Increased, Binding of chemicals to 2u (serum)	Molecular715	Activation, Constitutive androstane receptor	Activation, Constitutive androstane receptor	Molecular716	Increase, Mitogenic cell proliferation (hepatocytes)	Increase, Mitogenic cell proliferation (hepatocytes)	Cellular718	Binding, Tubulin	Binding, Tubulin	Molecular719	Increase, Adenomas/carcinomas (hepatocellular)	Increase, Adenomas/carcinomas (hepatocellular)	Tissue720	Depolymerization, Microtubule	Depolymerization, Microtubule	Molecular721	Disorganization, Spindle	Disorganization, Spindle	Cellular723	Altered, Chromosome number	Altered, Chromosome number	Cellular724	Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme	Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme	Cellular726	Increased, Induction of pyruvate dehydrogenase (PDH)	Increased, Induction of pyruvate dehydrogenase (PDH)	Molecular728	Increase, Aneuploid offspring	Increase, Aneuploid offspring	Individual733	Increase, Necrosis (terminal bronchiolar cells)	Increase, Necrosis (terminal bronchiolar cells)	Cellular734	Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells)	Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells)	Cellular735	Increase, Hyperplasia (terminal bronchiolar cells)	Increase, Hyperplasia (terminal bronchiolar cells)	Cellular736	Increase, Adenomas/carcinomas (bronchioloalveolar)	Increase, Adenomas/carcinomas (bronchioloalveolar)	Tissue737	Decreased, Uptake of inorganic iodide	Decreased, Uptake of inorganic iodide	Cellular739	Increase, Hypertrophy and proliferation (follicular cell)	Increase, Hypertrophy and proliferation (follicular cell)	Cellular740	Increase, Hyperplasia (follicular cells)	Increase, Hyperplasia (follicular cells)	Cellular741	Increase, Adenomas/carcinomas (follicular cell)	Increase, Adenomas/carcinomas (follicular cell)	Tissue742	Decreased, Androgen receptor activity	Decreased, Androgen receptor activity	Molecular743	Decreased, Testosterone binding to androgen receptor (hypothalamus)	Decreased, Testosterone binding to androgen receptor (hypothalamus)	Molecular744	Increase, Hyperplasia (Leydig cells)	Increase, Hyperplasia (Leydig cells)	Cellular745	Increase, Leydig cell tumors	Increase, Leydig cell tumors	Cellular746	Increase, Dopaminergic activity	Increase, Dopaminergic activity	Cellular747	Decreased, Prolactin	Decreased, Prolactin	Tissue748	Increased, Estrogen receptor (ER) activity	Increased, Estrogen receptor (ER) activity	Molecular749	Decreased, Progesterone from corpus luteum	Decreased, Progesterone from corpus luteum	Tissue752	Altered, Meiotic chromosome dynamics	Altered, Meiotic chromosome dynamics	Cellular753	Increase, Thyroid-stimulating hormone (TSH)	Increase, Thyroid-stimulating hormone (TSH)	Tissue754	Increased, Luteinizing hormone (LH) 	Increased, Luteinizing hormone (LH)	Tissue756	Hippocampal gene expression, Altered 	Hippocampal gene expression, Altered	Tissue757	Hippocampal anatomy, Altered 	Hippocampal anatomy, Altered	Tissue758	Hippocampal Physiology, Altered	Hippocampal Physiology, Altered	Tissue759	Increased, Kidney Failure	Increased, Kidney Failure	Individual760	Activation, Glutamate-gated chloride channel	Activation, Glutamate-gated chloride channel	Molecular761	Increased, Chloride conductance	Increased, Chloride conductance	Cellular762	Activation, ionotropic GABA Receptor chloride channel	Activation, ionotropic GABA Receptor chloride channel	Molecular763	hyperpolarisation, neuron	hyperpolarisation, neuron	Cellular764	N/A, Ataxia, paralysis, or hyperactivity	N/A, Ataxia, paralysis, or hyperactivity	Organ765	Decreased, population 1	Decreased, population 1	Population766	Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme	Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme	Molecular767	Increase, Hyperplasia (renal tubular cells)	Increase, Hyperplasia (renal tubular cells)	Cellular768	Increase, Cytotoxicity	Increase, Cytotoxicity	Cellular769	Increase, Oxidative metabolism	Increase, Oxidative metabolism	Cellular770	Increase, Cytotoxicity (club cells)	Increase, Cytotoxicity (club cells)	Cellular771	Decrease, Serum thyroid hormone (T4/T3)	Decrease, Serum thyroid hormone (T4/T3)	Tissue772	Increase, Hyperplasia (glandular epithelial cells of endometrium)	Increase, Hyperplasia (glandular epithelial cells of endometrium)	Cellular773	Increase, Endometrial adenocarcinomas	Increase, Endometrial adenocarcinomas	Tissue774	Increase, Preneoplastic foci (hepatocytes)	Increase, Preneoplastic foci (hepatocytes)	Cellular775	Increased, Plasma tyrosine	Increased, Plasma tyrosine	Tissue776	Increase, Cytotoxicity (corneal cells)	Increase, Cytotoxicity (corneal cells)	Cellular777	Increase, Inflammation (corneal cells)	Increase, Inflammation (corneal cells)	Cellular778	Increase, Regenerative cell proliferation (corneal cells)	Increase, Regenerative cell proliferation (corneal cells)	Cellular779	Increase, Papillomas/carcinomas (squamous cells)	Increase, Papillomas/carcinomas (squamous cells)	Cellular780	Increase, Cytotoxicity (epithelial cells)	Increase, Cytotoxicity (epithelial cells)	Cellular781	Increase, Regenerative cell proliferation (forestomach epithelial cells)	Increase, Regenerative cell proliferation (forestomach epithelial cells)	Cellular782	Increase, Hyperplasia (forestomach epithelial cells)	Increase, Hyperplasia (forestomach epithelial cells)	Cellular783	Increase, Cytotoxicity (tubular epithelial cells)	Increase, Cytotoxicity (tubular epithelial cells)	Cellular784	Increase, Hyperplasia (tubular epithelial cells)	Increase, Hyperplasia (tubular epithelial cells)	Cellular785	Activation, Androgen receptor	Activation, Androgen receptor	Molecular786	Increase, Cytotoxicity (hepatocytes)	Increase, Cytotoxicity (hepatocytes)	Cellular787	Increase, Regenerative cell proliferation (hepatocytes)	Increase, Regenerative cell proliferation (hepatocytes)	Cellular788	Decrease, Incorporation of active iodide into iodotyrosines	Decrease, Incorporation of active iodide into iodotyrosines	Cellular790	Inhibition, 5_-reductase activity	Inhibition, 5_-reductase activity	Cellular791	Increased, Leutinizing hormone (LH)	Increased, Leutinizing hormone (LH)	Tissue792	Decrease, Bioactivation of testosterone	Decrease, Bioactivation of testosterone	Tissue793	Increase, Urinary bladder calculi	Increase, Urinary bladder calculi	Organ794	Increase, Cytotoxicity (urothelial cells)	Increase, Cytotoxicity (urothelial cells)	Cellular795	Increase, Regenerative cell proliferation (urothelial cells)	Increase, Regenerative cell proliferation (urothelial cells)	Cellular796	Increase, Hyperplasia (urothelial)	Increase, Hyperplasia (urothelial)	Cellular797	Increase, Adenomas/carcinomas (urothelial)	Increase, Adenomas/carcinomas (urothelial)	Tissue798	Inhibition, Prolyl hydroxylases	Inhibition, Prolyl hydroxylases	Cellular799	Increased, HIF-1 heterodimer	Increased, HIF-1 heterodimer	Cellular800	Decreased, Aromatase (Cyp19a1) mRNA	Decreased, Aromatase (Cyp19a1) mRNA	Cellular801	modulation, Unknown	modulation, Unknown	Molecular802	Increased, HIF-1 alpha transcription	Increased, HIF-1 alpha transcription	Cellular804	Inhibition, HMG-CoA reductase	Inhibition, HMG-CoA reductase	Cellular805	Decreased, mevalonate	Decreased, mevalonate	Cellular807	Decreased, cholesterol	Decreased, cholesterol	Cellular808	Decreased, Testosterone	Decreased, Testosterone	Individual809	malformed, Male reproductive tract	malformed, Male reproductive tract	Individual813	Increased, Serum creatinine	Increased, Serum creatinine	Organ814	Occurrence, Kidney toxicity	Occurrence, Kidney toxicity	Organ818	Occurrence, Cytoplasmic vacuolization (Renal tubule)	Occurrence, Cytoplasmic vacuolization (Renal tubule)	Organ819	Decreased, Glomerular filtration	Decreased, Glomerular filtration	Tissue820	Decreased, Renal plasma flow	Decreased, Renal plasma flow	Tissue821	Decreased, Sodium reabsorption	Decreased, Sodium reabsorption	Organ823	Occurrence, Cystic dilatation (renal tubule)	Occurrence, Cystic dilatation (renal tubule)	Organ824	Occurrence, Cytoplasmic vacuolization (podocyte)	Occurrence, Cytoplasmic vacuolization (podocyte)	Organ825	Decreased, Renal ability to dilute urine	Decreased, Renal ability to dilute urine	Organ826	Activation, Keratinocytes	Activation, Keratinocytes	Cellular827	sensitisation, skin	sensitisation, skin	Organ828	Inhibition, Phospholipase A	Inhibition, Phospholipase A	Molecular829	Damage, Lipid bilayer	Damage, Lipid bilayer	Cellular831	Disturbance, Lysosomal function	Disturbance, Lysosomal function	Cellular832	Injury, Mitochondria	Injury, Mitochondria	Cellular833	Occurrence, Cytoplasmic vacuolization (hepatocyte)	Occurrence, Cytoplasmic vacuolization (hepatocyte)	Cellular835	Occurrence, Ballooning degeneration (hepatocyte)	Occurrence, Ballooning degeneration (hepatocyte)	Cellular836	Occurrence, Cytoplasmic vacuolization (Bile duct cell)	Occurrence, Cytoplasmic vacuolization (Bile duct cell)	Cellular837	Occurrence, Cytoplasmic vacuolization (kupffer cell)	Occurrence, Cytoplasmic vacuolization (kupffer cell)	Cellular838	Induction, Microvesicular fat	Induction, Microvesicular fat	Tissue839	Formation, Mallory body	Formation, Mallory body	Cellular840	Formation, Liver fibrosis	Formation, Liver fibrosis	Tissue844	Oxidation, Uroporphyrinogen	Oxidation, Uroporphyrinogen	Cellular845	Inhibition, UROD	Inhibition, UROD	Molecular846	Accumulation, Highly carboxylated porphyrins	Accumulation, Highly carboxylated porphyrins	Organ848	Decreased, Binding of NE to NE receptors on GnRH neurons	Decreased, Binding of NE to NE receptors on GnRH neurons	Cellular849	Inhibition, Antgonism of NE receptor	Inhibition, Antgonism of NE receptor	Molecular850	Induction, CYP1A2/CYP1A5	Induction, CYP1A2/CYP1A5	Molecular851	Decrease of GABAergic interneurons	GABAergic interneurons, Decreased	Cellular853	Changes/Inhibition, Cellular Homeostasis and Apoptosis	Changes/Inhibition, Cellular Homeostasis and Apoptosis	Cellular854	Alterations, Cellular proliferation / hyperplasia	Alterations, Cellular proliferation / hyperplasia	Tissue856	Formation, Hepatocellular and Bile duct tumors	Formation, Hepatocellular and Bile duct tumors	Organ857	Binding as antagonist, Antagonist binding to PPARalpha ligand binding domain	Binding as antagonist, Antagonist binding to PPARalpha ligand binding domain	Molecular858	Decreased, PPARalpha transactivation of gene expression	Decreased, PPARalpha transactivation of gene expression	Molecular859	Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids	Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids	Molecular860	Decreased, Mitochondrial Fatty Acid Beta Oxidation	Decreased, Mitochondrial Fatty Acid Beta Oxidation	Molecular861	Decreased, Ketogenesis (production of ketone bodies)	Decreased, Ketogenesis (production of ketone bodies)	Cellular862	Not Increased, Circulating Ketone Bodies	Not Increased, Circulating Ketone Bodies	Tissue863	Increased, Catabolism of Muscle Protein	Increased, Catabolism of Muscle Protein	Organ864	Decreased, Body Weight	Decreased, Body Weight	Individual867	Decrease, Intracellular pH	Decrease, Intracellular pH	Cellular868	Increase, Tissue Degeneration, Necrosis & Atrophy 	Increase, Tissue Degeneration, Necrosis & Atrophy	Tissue869	Increase, Respiratory or Squamous Metaplasia	Increase, Respiratory or Squamous Metaplasia	Tissue870	Increase, Cell Proliferation	Increase, Cell Proliferation	Cellular872	Increase, Site of Contact Nasal Tumors	Increase, Site of Contact Nasal Tumors	Organ875	Binding of agonist, Ionotropic glutamate receptors	Binding of agonist, Ionotropic glutamate receptors	Molecular876	Increase, Mutations in Critical Genes	Increase, Mutations in Critical Genes	Molecular877	Inhibition, organic anion transporter 1 (OAT1)	Inhibition, organic anion transporter 1 (OAT1)	Molecular878	Inhibition, SREBP1c	Inhibition, SREBP1c	Molecular879	Activation, MTTP	Activation, MTTP	Cellular880	Increased, ApoB100	Increased, ApoB100	Tissue881	Increased, Triglyceride	Increased, Triglyceride	Cellular885	Increase, Cancer	Increase, Cancer	Tissue887	Inhibition, NADH-ubiquinone oxidoreductase (complex I)	Inhibition, NADH-ubiquinone oxidoreductase (complex I)	Cellular888	Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I)	Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I)	Molecular889	Impaired, Proteostasis	Impaired, Proteostasis	Cellular890	Degeneration of dopaminergic neurons of the nigrostriatal pathway	Degeneration of dopaminergic neurons of the nigrostriatal pathway	Organ896	Parkinsonian motor deficits	Parkinsonian motor deficits	Individual898	Disruption, Lysosome	Disruption, Lysosome	Cellular901	Infiltration, Inflammatory cells	Infiltration, Inflammatory cells	Tissue902	Inflammation, Liver	Inflammation, Liver	Organ907	Infiltration, Inflammatory cytokines	Infiltration, Inflammatory cytokines	913	Activation, Epidermal Growth Factor Receptor	Activation, Epidermal Growth Factor Receptor	914	Decrease, Apoptosis of ciliated epithelial cells	Decrease, Apoptosis of ciliated epithelial cells	Cellular919	Occurrence, Transdifferentiation of ciliated epithelial cells	Occurrence, Transdifferentiation of ciliated epithelial cells	Cellular920	Occurrence, Metaplasia of goblet cells	Occurrence, Metaplasia of goblet cells	Tissue921	Occurrence, Hyperplasia of goblet cells	Goblet cell hyperplasia	Tissue923	Increase, Proliferation of goblet cells	Increase, Proliferation of goblet cells	Cellular924	Activation, SP1	Activation, SP1	Molecular926	Oxidation, Glutathione	Oxidation, Glutathione	Molecular927	S-Glutathionylation, eNOS	S-Glutathionylation, eNOS	Molecular932	Uncoupling, eNOS	Uncoupling, eNOS	Cellular933	Depletion, Nitric Oxide	Depletion, Nitric Oxide	Cellular934	Decrease, Tetrahydrobiopterin	Decrease, Tetrahydrobiopterin	Cellular935	Decrease, GTPCH-1	Decrease, GTPCH-1	Cellular937	impaired, Vasodilation	impaired, Vasodilation	Organ941	Activation, EGFR	Activation, EGFR	Molecular943	Hypersecretion, Mucus	Hypersecretion, Mucus	Organ944	dimerization, AHR/ARNT	dimerization, AHR/ARNT	Molecular945	reduced dimerization, ARNT/HIF1-alpha	reduced dimerization, ARNT/HIF1-alpha	Molecular947	Increase, Embryolethality	Increase, Embryolethality	Individual948	reduced production, VEGF	reduced production, VEGF	Cellular951	Increase, Vascular Resistance	Increase, Vascular Resistance	Organ952	Hypertension	Hypertension	Individual957	Binding, Transthyretin in serum	Binding, Transthyretin in serum	Molecular958	Displacement, Serum thyroxine (T4) from transthyretin	Displacement, Serum thyroxine (T4) from transthyretin	Molecular959	Increased, Free serum thyroxine (T4)	Increased, Free serum thyroxine (T4)	Tissue960	Increased, Uptake of thyroxine into tissue	Increased, Uptake of thyroxine into tissue	Cellular961	Increased, Clearance of thyroxine from tissues	Increased, Clearance of thyroxine from tissues	Tissue962	Increase, Mucin production	Increase, Mucin production	Cellular964	Inhibition of Aromatase Enzyme, Chemical exposure during critical window of estrous cycle between diestrus 2 and proestrus inhibits aromatase conversion of testosterone to estradiol	Inhibition of Aromatase Enzyme, Chemical exposure during critical window of estrous cycle b	Molecular965	reduction in ovarian granulosa cells synthesis of estradiol, Reduced steroidogenic production of estradiol in granulosa cells	reduction in ovarian granulosa cells synthesis of estradiol, Reduced steroidogenic producti	Cellular966	Reduced Estradiol in Circulation, Reduced steroidogenic production of estradiol in granulosa cells leading to decreased estradiol in circulation	Reduced Estradiol in Circulation, Reduced steroidogenic production of estradiol in granulos	Tissue967	Decreased positive estrogenic feedback on hypothalamus, Reduced estradiol in circulation decreases estrogen concentration at hypothalamus	Decreased positive estrogenic feedback on hypothalamus, Reduced estradiol in circulation de	Organ968	Decreased Kisspeptin release from neurons in AVPV, Decreased hypothalamic estrogen reduces kisspeptinergic neuron response 	Decreased Kisspeptin release from neurons in AVPV, Decreased hypothalamic estrogen reduces	Cellular969	Decreased GnRH Release, Decreased Kisspeptin stimulation of GnRH neurons 	Decreased GnRH Release, Decreased Kisspeptin stimulation of GnRH neurons	Cellular970	Decreased LH release from Anterior Pituitary, Decreased GnRH stimulation of Anterior Pituitary Gonadotrophs	Decreased LH release from Anterior Pituitary, Decreased GnRH stimulation of Anterior Pituit	Cellular971	Ovulation of oocytes Reduced, Delayed, or Blocked, Decrease or delay in LH surge required for ovulation 	Ovulation of oocytes Reduced, Delayed, or Blocked, Decrease or delay in LH surge required f	Individual972	Decreased fertility, Reduced number of oocytes ovulated 	Decreased fertility, Reduced number of oocytes ovulated	Individual973	Decrease, Akt/eNOS activity	Decrease, Akt/eNOS activity	Cellular974	The binding of FK506 with FKBP12, 	The binding of FK506 with FKBP12,	975	The binding of FK506 with FKBP12, The binding of FK506 with FKBP12	The binding of FK506 with FKBP12, The binding of FK506 with FKBP12	976	Formation, The binding of FK506 with FKBP12	Formation, The binding of FK506 with FKBP12	Molecular977	Binding, Binding of calcineurin with FK506-FKBP complexes	Binding, Binding of calcineurin with FK506-FKBP complexes	978	Activation, Suppression of NFAT activation and hindrance of nuclear localization	Activation, Suppression of NFAT activation and hindrance of nuclear localization	Molecular979	Interference, nuclear localization of NFAT	Interference, nuclear localization of NFAT	Molecular980	Inhibition, Calcineurin Activity	Inhibition, Calcineurin Activity	Molecular981	Reduction, NFAT complex formation	Reduction, NFAT complex formation	Cellular982	Suppression, Suppression in mixed lymphocyte reaction (MLR)	Suppression, Suppression in mixed lymphocyte reaction (MLR)	Cellular983	Suppression, Suppression of T-cell dependent antibody response (TDAR) 	Suppression, Suppression of T-cell dependent antibody response (TDAR)	Cellular984	Impairment, T-cell dependent antibody response	Impairment, T-cell dependent antibody response	Individual985	Relief, Relief of atopic dermatitis	Relief, Relief of atopic dermatitis	Individual986	Increase, Increased susceptibility to infection	Increase, Increased susceptibility to infection	Individual987	, Metaplasia of goblet cells	, Metaplasia of goblet cells	988	Reduction, Release of circulating ecdysis triggering hormone	Reduction, Release of circulating ETH	Tissue989	Decreased, synthesis and secretion of molting fluid proteases	Decreased, synthesis and secretion of molting fluid proteases	990	Induction, Incomplete ecdysis	Induction, Incomplete ecdysis	Individual991	Increased, Alterations of food-web structures	Increased, Alterations of food-web structures	992	Decreased, Population 2	Decreased, Population 2	993	Reduction, Abdominal muscle contraction	Reduction, Abdominal muscle contraction	Tissue994	Decreased, Synthesis of molting fluid proteases	Decreased, Synthesis of molting fluid proteases	Tissue995	Alterations, Food-web structures	Alterations, Food-web structures	Population996	Decreased, Digestion of old cuticle	Decreased, Digestion of old cuticle	Organ997	Decreased, Population size	Decreased, Population size	Population998	Binding of antagonist, PPAR alpha	Binding of antagonist, PPAR alpha	Molecular999	stabilization, co-repressor	stabilization, co-repressor	1000	stabilization, PPAR alpha co-repressor	stabilization, PPAR alpha co-repressor	Molecular1001	Increased, Developmental Defects	Increased, Developmental Defects	Molecular1002	Inhibition, Deiodinase 2	Inhibition, Deiodinase 2	Molecular1003	Decreased, Triiodothyronine (T3) in serum	Decreased, Triiodothyronine (T3) in serum	Cellular1004	Reduced, Posterior swim bladder inflation	Reduced, Posterior swim bladder inflation	Organ1005	Reduced, Swimming performance	Reduced, Swimming performance	Individual1006	Reduced, Young of year survival	Reduced, Young of year survival	Individual1007	Reduced, Anterior swim bladder inflation	Reduced, Anterior swim bladder inflation	Tissue1008	Reduced, Hearing	Reduced, Hearing	Organ1009	Inhibition, Deiodinase 1	Inhibition, Deiodinase 1	Molecular1010	Activation, iGABAR chloride channel 	Activation, iGABAR chloride channel	1011	Increased, Chloride influx	Increased, Chloride influx	1012	Increased, Inhibitory postsynaptic potential	Increased, Inhibitory postsynaptic potential	Cellular1013	Inhibition, Motor neuron activity	Inhibition, Motor neuron activity	1014	Induction, Somatic muscle paralysis	Induction, Somatic muscle paralysis	Tissue1015	Increased, Neuronal synaptic inhibition	Increased, Neuronal synaptic inhibition	Cellular1016	Inhibition, Feeding	Inhibition, Feeding	Individual1017	Reduced, Feeding 2	Reduced, Feeding 2	1018	Activation, Glutamate-gated chloride channels	Activation, Glutamate-gated chloride channels	Molecular1019	Induction, pharyngeal muscle paralysis	Induction, pharyngeal muscle paralysis	Tissue1020	Increased, induction of UDPGT's in liver	Increased, induction of UDPGT's in liver	Cellular1021	Increased, T4/T3 catabolism	Increased, T4/T3 catabolism	Cellular1022	Decreased, serum T4/T3	Decreased, serum T4/T3	Tissue1023	Increased, Thyroid-stimulating hormone (TSH)	Increased, Thyroid-stimulating hormone (TSH)	Tissue1024	Increased, Hypertrophy and proliferation (follicular cell)	Increased, Hypertrophy and proliferation (follicular cell)	Cellular1025	Increased, Hyperplasia (follicular cells)	Increased, Hyperplasia (follicular cells)	Tissue1026	Increased Apoptosis, Adenomas/carcinomas (follicular cell)	Increased Apoptosis, Adenomas/carcinomas (follicular cell)	Tissue1027	, Learning and memory, impairment	, Learning and memory, impairment	1028	Activation of specific nuclear receptors, PPAR-gamma activation	Activation of specific nuclear receptors, PPAR-gamma activation	Molecular1029	Increased, adipogenesis	Increased, adipogenesis	Cellular1030	Increased, 	Increased,	1031	Increased, release of growth factors	Increased, release of growth factors	1032	Increased, secretion of local growth factors	Increased, secretion of local growth factors	Cellular1033	Increased, proliferation of mesenchymal cells	Increased, proliferation of mesenchymal cells	Cellular1034	Increased, IGF-1 (mouse)	Increased, IGF-1 (mouse)	Cellular1035	Increased, Firbrosarcoma	Increased, Firbrosarcoma	Tissue1036	Increased, liposarcoma	Increased, liposarcoma	Tissue1037	Increased, hemagiosarcoma	Increased, hemagiosarcoma	Tissue1038	Activation, beta-2 adrenergic receptor	Activation, beta-2 adrenergic receptor	Molecular1039	Increased activity, beta-2 adrenergic receptor	Increased activity, beta-2 adrenergic receptor	Molecular1040	relaxation, smooth muscle	relaxation, smooth muscle	Tissue1041	Proliferation, smooth muscle	Proliferation, smooth muscle	1042	Proliferation/Clonal Expansion, smooth muscle	Proliferation/Clonal Expansion, smooth muscle	Cellular1043	Hypertrophy/hyperplasia, smooth muscle	Hypertrophy/hyperplasia, smooth muscle	Cellular1044	Promotion, mesovarian leiomyomas	Promotion, mesovarian leiomyomas	Tissue1045	Decreased, Ovarian E2	Decreased, Ovarian E2	Tissue1046	Suppression, Estrogen receptor (ER) activity	Suppression, Estrogen receptor (ER) activity	Molecular1047	Increased, secretion of GnRH from hypothalamus	Increased, secretion of GnRH from hypothalamus	Cellular1048	Increased, secretion of leutenizing hormone	Increased, secretion of leutenizing hormone	1049	Increased, secrection of FSH from anterior pituitary	Increased, secrection of FSH from anterior pituitary	Cellular1050	Increased, secretion of LH from anterior pituitary	Increased, secretion of LH from anterior pituitary	Cellular1051	Hyperplasia, ovarian stromal cells	Hyperplasia, ovarian stromal cells	Cellular1052	Hyperplasia, ovarian epithelium	Hyperplasia, ovarian epithelium	Tissue1053	Promotion, ovarian adenomas	Promotion, ovarian adenomas	Tissue1054	Promotion, ovarian granular cell tumors	Promotion, ovarian granular cell tumors	Cellular1055	Decreased, Reduced estradiol in circulation decreases estrogen concentration at hypothalamus	Decreased, Reduced estradiol in circulation decreases estrogen concentration at hypothalamu	1056	Decrease, E2 blood concentrations at hypothalamus	Decrease, E2 blood concentrations at hypothalamus	Tissue1057	Increased, PPAR-alpha activation	Increased, PPAR-alpha activation	Molecular1058	Decreased, bile flow	Decreased, bile flow	Organ1059	Increased, cholestasis	Increased, cholestasis	Organ1060	Alteration, lipid metabolism	Alteration, lipid metabolism	Cellular1061	prolonged, elevation of serun CCK	prolonged, elevation of serun CCK	Tissue1062	Increased, Cellular proliferation / hyperplasia of acinar cells	Increased, Cellular proliferation / hyperplasia of acinar cells	Cellular1063	Increased, Pancreatic acinar tumors	Increased, Pancreatic acinar tumors	Organ1064	prepubertal increase, Estrogen receptor (ER) activity	prepubertal increase, Estrogen receptor (ER) activity	Molecular1065	Activation, estrogen receptor alpha	Activation, estrogen receptor alpha	Molecular1066	Promotion, SIX-1 postive basal-type progenitor cells	Promotion, SIX-1 postive basal-type progenitor cells	Cellular1067	Proliferation/Clonal Expansion, aberrant basal cells	Proliferation/Clonal Expansion, aberrant basal cells	Cellular1068	squamous metaplasia, aberrant basal cells	squamous metaplasia, aberrant basal cells	Tissue1069	Increased, Hyperplasia (glandular epithelial cells of endometrium)	Increased, Hyperplasia (glandular epithelial cells of endometrium)	Cellular1070	Increased, adenosquamous carcinomas of endometrium	Increased, adenosquamous carcinomas of endometrium	Tissue1071	Decreased, GnRH pulsatility/release in hypothalamus	Decreased, GnRH pulsatility/release in hypothalamus	Cellular1072	Decreased, LH Surge from anterior pituitary	Decreased, LH Surge from anterior pituitary	Cellular1073	anovulation, 	anovulation,	1074	interruption, Ovulation	interruption, Ovulation	Individual1075	prolonged, estrus	prolonged, estrus	Individual1076	Increased, circulating estrogen levels	Increased, circulating estrogen levels	Organ1077	Increased, prolactin exposure	Increased, prolactin exposure	Tissue1078	Hyperplasia, Mammary gland	Hyperplasia, Mammary gland	Tissue1079	Increased, Adenomas/carcinomas (mammary)	Increased, Adenomas/carcinomas (mammary)	Tissue1080	Increased, latency period	Increased, latency period	Individual1081	Increased, lactotroph hyperplasia and hypertrophy	Increased, lactotroph hyperplasia and hypertrophy	Cellular1082	Increased, adenomas (pituitary)	Increased, adenomas (pituitary)	Tissue1083	Decreased, Dopaminergic activity	Decreased, Dopaminergic activity	Cellular1084	Increased, prolactin secretion	Increased, prolactin secretion	Tissue1085	Increased, hyperplasia (mammary gland)	Increased, hyperplasia (mammary gland)	Tissue1086	persistent, cytotoxicity (pleura or peritoneum)	persistent, cytotoxicity (pleura or peritoneum)	Cellular1087	Increased, inflammation	Increased, inflammation	Cellular1088	Increased, Oxidative Stress	Increased, Oxidative Stress	Cellular1089	Increased, Cell Proliferation (mesothelium)	Increased, Cell Proliferation (mesothelium)	Cellular1090	Increased, mesotheliomas	Increased, mesotheliomas	Tissue1091	Physical and/or chemical interaction with cellular components, 	Physical and/or chemical interaction with cellular components,	1092	Pulmonary Fibrosis, 	Pulmonary Fibrosis,	1093	Decreased, Thyroxine (T4) in tissues	Decreased, Thyroxine (T4) in tissues	Tissue1094	, hyperuricemia	, hyperuricemia	1095	hyperuricemia, 	hyperuricemia,	1096	Increased, blood uric acid concentration	Increased, blood uric acid concentration	Tissue1097	Occurrence, renal proximal tubular necrosis	Occurrence, renal proximal tubular necrosis	Tissue1098	Increased, blood potassium concentration	Increased, blood potassium concentration	Tissue1099	Increased, mortality 2	Increased, mortality 2	1100	Occurrence, cardiac arrthymia	Occurrence, cardiac arrthymia	1101	Altered, Amphibian metamorphosis	Altered, Amphibian metamorphosis	Organ1102	Occurrence, tophi (urate) deposition	Occurrence, tophi (urate) deposition	Tissue1103	Inhibition, Cyclooxygenase 1 activity	Inhibition, Cyclooxygenase 1 activity	Molecular1104	Decreased, Prostaglandin F2alpha concentration, plasma 	Decreased, Prostaglandin F2alpha concentration, plasma	Tissue1105	Occurrence, renal ischemia	Occurrence, renal ischemia	Tissue1106	Occurrence, cardiac arrhythmia	Occurrence, cardiac arrhythmia	Organ1107	Weakened, Colony	Weakened, Colony	Population1108	Abnormal, Role change within caste	Abnormal, Role change within caste	Population1109	Increased, Deformed Wing Virus levels	Increased, Deformed Wing Virus levels	Individual1110	Increased, Energetic demands and therefore metabolic stress	Increased, Energetic demands and therefore metabolic stress	Individual1111	weaj, 	weaj,	1112	Occurrence, Oxidative Stress	Occurrence, Oxidative Stress	1113	Unknown, 	Unknown,	1114	Unknown, MIE	Unknown, MIE	Molecular1115	Increased, Reactive oxygen species	Increased, Reactive oxygen species	Cellular1116	Decreased, Triiodothyronine (T3) in tissues	Decreased, Triiodothyronine (T3) in tissues	Tissue1117	Irreversible inhibition of VKOR by binding at tyrosine 139, 	Irreversible inhibition of VKOR by binding at tyrosine 139,	1118	Irreversible inhibition of VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone	Irreversible inhibition of VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin	1119	Failure in gamma-glutamyl carboxylation of glutamine residues on clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin) 	Failure in gamma-glutamyl carboxylation of glutamine residues on clotting factors II, VII,	1120	Under carboxylated clotting factors will not assemble on cell surfaces , Failure to form clot	Under carboxylated clotting factors will not assemble on cell surfaces , Failure to form cl	1121	Hemorrhage , organ dysfunction, hypovolemic shock	Hemorrhage , organ dysfunction, hypovolemic shock	1122	Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failure of secondary hemostasis 	Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failur	Tissue1123	Hemorrhage, organ dysfunction, hypovolemic shock, Impaired oxygen delivery to tissue	Hemorrhage, organ dysfunction, hypovolemic shock, Impaired oxygen delivery to tissue	1124	Hemorrhage , Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal	Hemorrhage , Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon diox	1125	Impaired oxygen and nutrient delivery to tissue, impaired removal of carbon dioxide and other waste products, Hemorrhage, organ dysfunction and hypovolemic shock 	Impaired oxygen and nutrient delivery to tissue, impaired removal of carbon dioxide and oth	1126	Unresolved blood loss, Failure in vascular repair mechanisms 	Unresolved blood loss, Failure in vascular repair mechanisms	1127	Anemia, Impaired oxygen and nutrient delivery to tissue, impaired carbon dioxide and waste product removal	Anemia, Impaired oxygen and nutrient delivery to tissue, impaired carbon dioxide and waste	1128	Unresolved hemorrhage, Failure in vascular repair mechanisms 	Unresolved hemorrhage, Failure in vascular repair mechanisms	1129	Unresolved blood loss (hemorrhage), Failure in vascular repair mechanisms 	Unresolved blood loss (hemorrhage), Failure in vascular repair mechanisms	1130	Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)	Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)	Organ1131	Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin) 	Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo	Molecular1132	Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal	Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis	Cellular1133	Hemostasis, Depletion from blood of fully functional carboxylated clotting factors	Hemostasis, Depletion from blood of fully functional carboxylated clotting factors	Tissue1134	Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone	Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle	Molecular1135	Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction	Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction	Tissue1136	Impaired recruitment , Population trajectory	Impaired recruitment , Population trajectory	Population1137	Under carboxylation of osteocalcin, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone	Under carboxylation of osteocalcin, Failure to cycle vitamin K epoxide to vitamin K to form	1138	Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP	Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP	Molecular1139	Increased, water retention in foot	Increased, water retention in foot	Organ1140	Delayed, Sexual maturity	Delayed, Sexual maturity	Individual1141	Decreased, Reproductive Success	Decreased, Reproductive Success	Individual1142	Increased, valve movement	Increased, valve movement	Tissue1143	Depletion, energy reserves	Depletion, energy reserves	Individual1144	premature, spawning 1 1	premature, spawning 1	1145	Decreased, gametogenesis	Decreased, gametogenesis	1146	premature, Spawning 	premature, Spawning	Individual1147	increased or inappropriate, mantel display	increased or inappropriate, mantel display	Individual1148	Anticoagulant rodenticide interferes with gamma-carboxyglutamate formation, Inhibition of protein synthesis in bone	Anticoagulant rodenticide interferes with gamma-carboxyglutamate formation, Inhibition of p	1149	Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone proteins (periostin, MGP and periostin like factor) not formed 	Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone protei	1150	Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Impaired function of osteocalcin and MGP	Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Imp	1151	Osteoporosis and vascular calcification, Bone deterioration	Osteoporosis and vascular calcification, Bone deterioration	Individual1152	Inhibition, Iodotyrosine deiodinase (IYD)	Inhibition, Iodotyrosine deiodinase (IYD)	Molecular1153	Inhibition, Deiodinase 3	Inhibition, Deiodinase 3	Molecular1154	Increased, Triiodothyronine (T3) in tissues	Increased, Triiodothyronine (T3) in tissues	Tissue1155	Inhibition, Pendrin	Inhibition, Pendrin	Molecular1156	Inhibition, Dual oxidase	Inhibition, Dual oxidase	Molecular1157	Activation, Hepatic nuclear receptor(s)	Activation, Hepatic nuclear receptor(s)	Molecular1158	Increased, Hepatic thyroid hormone uptake/transport	Increased, Hepatic thyroid hormone uptake/transport	Tissue1159	"Increased, reuptake of 5-HT (5-hydroxytryptamine transporter; sodium-dependent serotonin transporter"	"Increased, reuptake of 5-HT (5-hydroxytryptamine transporter; sodium-dependent serotonin tr"	1160	Increased, mantel display	Increased, mantel display	Individual1161	Increased, oocyte maturation	Increased, oocyte maturation	Organ1162	Increased, cilia movement	Increased, cilia movement	Cellular1163	Increased, Reproductive Success	Increased, Reproductive Success	Individual1164	Increased, Population	Increased, Population	Population1165	Vitamin K inhibition, gamma-carboxylation of glutamate to Gla residues reduced in bone proteins e.g., periostin 	Vitamin K inhibition, gamma-carboxylation of glutamate to Gla residues reduced in bone prot	1166	Increased, water pumping	Increased, water pumping	Tissue1167	induced, parturition	induced, parturition	Individual1168	Undercarboxylation of osteocalcin , Affects bone formation (osteoblast-osteoclast interaction, bone resorption) and glucose and lipid hoemostasis	Undercarboxylation of osteocalcin , Affects bone formation (osteoblast-osteoclast interacti	1169	Anticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, Impairment of post-translational modification (carboxylation) of osteocalcin	Anticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, Impairment	Molecular1170	modulation, Genes/proteins that regulate hepatocyte fate	modulation, Genes/proteins that regulate hepatocyte fate	Cellular1171	Increase, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci	Increase, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci	Cellular1172	Increase activation, Nuclear factor kappa B (NF-kB)	Increase activation, Nuclear factor kappa B (NF-kB)	Molecular1173	Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids	Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids	Molecular1174	Activation, NADPH Oxidase	Activation, NADPH Oxidase	Molecular1175	Increase, Genes involved in fatty acid oxidation	Increase, Genes involved in fatty acid oxidation	Cellular1176	Decreased, sodium conductance 2	Decreased, sodium conductance 2	Cellular1177	Decreased, Ionotropic GABA receptor chloride channel conductance	Decreased, Ionotropic GABA receptor chloride channel conductance	Cellular1178	Decreased, Chloride conductance	Decreased, Chloride conductance	1179	Decreased, GABA release	Decreased, GABA release	Cellular1180	Estrogen receptor activation, 	Estrogen receptor activation,	1181	Activation, Estrogen receptor	Activation, Estrogen receptor	Molecular1182	Increase, Cell Proliferation (Epithelial Cells)	Increase, Cell Proliferation (Epithelial Cells)	Cellular1183	Decreased, Apoptosis (Epithelial Cells)	Decreased, Apoptosis (Epithelial Cells)	Cellular1184	Dysfunction, Mitochondrial Dynamics	Dysfunction, Mitochondrial Dynamics	1185	Mitochondrial Dysfunction, N/A	Mitochondrial Dysfunction, N/A	1186	N/A, Mitochondrial Dysfunction 2	N/A, Mitochondrial Dysfunction 2	1187	Increased, ER binding to DNA (classical pathway) 	Increased, ER binding to DNA (classical pathway)	Molecular1188	Increased, ER binding to T.F. to DNA (non-classical pathway)	Increased, ER binding to T.F. to DNA (non-classical pathway)	Molecular1189	Increased, Proliferation (Endothelial cells) 	Increased, Proliferation (Endothelial cells)	Cellular1190	Increased, Migration (Endothelial Cells)	Increased, Migration (Endothelial Cells)	Cellular1191	Increased, Non-genomic signaling	Increased, Non-genomic signaling	Cellular1192	Increased, Ductal Hyperplasia 	Increased, Ductal Hyperplasia	Tissue1193	N/A, Breast Cancer	N/A, Breast Cancer	Individual1194	Increase, DNA damage	Increase, DNA Damage	Molecular1195	modulation, Extracellular Matrix Composition 	modulation, Extracellular Matrix Composition	Cellular1196	Increased, Invasion	Increased, Invasion	Cellular1197	Activation, Fibroblasts	Activation, Fibroblasts	Cellular1198	Activation, Macrophages	Activation, Macrophages	Cellular1199	Binding of FK506 to FKBP12, 	Binding of FK506 to FKBP12,	1200	Binding of FK506 to FKBP12, Formation	Binding of FK506 to FKBP12, Formation	1201	Binding, Immunophilins	Binding, Immunophilins	Molecular1202	Suppression, IL-2 and IL-4 production	Suppression, IL-2 and IL-4 production	Cellular1203	Suppression, Suppression of production of cytotoxic T-cells	Suppression, Suppression of production of cytotoxic T-cells	Tissue1204	Suppression, Suppression of T-cell dependent antibody production	Suppression, Suppression of T-cell dependent antibody production	Cellular1205	Activation, Juvenile hormone receptor	Activation, Juvenile hormone receptor	Molecular1206	Induction, Doublesex1 gene	Induction, Doublesex1 gene	Molecular1207	Induction, Male traits formation in embryos	Induction, Male traits formation in embryos	1208	Increased, Male offspring	Increased, Male offspring	Population1209	Induction, Male reproductive tract	Induction, Male reproductive tract	Organ1210	Alteration, Food-web structures	Alteration, Food-web structures	Population1211	Altered, food-web structures	Altered, food-web structures	Population1212	Reduced, Neuronal synaptic inhibition	Reduced, Neuronal synaptic inhibition	Cellular1213	Increased, Angiogenesis	Increased, Angiogenesis	Cellular1214	Altered gene expression specific to CAR activation, Hepatocytes	Altered gene expression specific to CAR activation, Hepatocytes	Cellular1215	TRPA1 activation, TRPA1 Receptor	TRPA1 activation, TRPA1 Receptor	Molecular1216	Influx of Ca2+, Excitation of trigeminal nerves	Influx of Ca2+, Excitation of trigeminal nerves	1217	Sensory airway irritation, Excitation of trigeminal nerves	Sensory airway irritation, Excitation of trigeminal nerves	1218	Opening of calcium channel, Calcium influx	Opening of calcium channel, Calcium influx	Cellular1219	Release of Substance P (SP), Substance P increase in circulation	Release of Substance P (SP), Substance P increase in circulation	1220	Excitation, Neuron nerve ending excitation	Excitation, Neuron nerve ending excitation	Tissue1221	Cough, Dyspnea, Sneezing, Acute respiratory effect	Cough, Dyspnea, Sneezing, Acute respiratory effect	1222	SP (Substance P) release, Local increase of SP	SP (Substance P) release, Local increase of SP	Cellular1223	Trigeminal and/or vagal nerve excitation	Nerve excitation	Tissue1224	Non-neuronal production of TNF, Epithelial irritation	Non-neuronal production of TNF, Epithelial irritation	Individual1225	Immune system inflammation 	Leukocyte infiltration	Tissue1226	Chronic Cough, Respiratory irritability	Chronic Cough, Respiratory irritability	Individual1227	TRPA1 activation, Chemical covalent binding to sulfhydyl group on TRPA1 receptor protein/NEK293 fibroblast cells	TRPA1 activation, Chemical covalent binding to sulfhydyl group on TRPA1 receptor protein/NE	1228	TRPA1 activation, Classic receptor binding / HEK 293 cells (fibroclast), cho cells (ovary), noncovalently linkked)	TRPA1 activation, Classic receptor binding / HEK 293 cells (fibroclast), cho cells (ovary),	1229	TRPA1 activation, Chemical covalent binding to sulfhydyl group on TRPA1 receptor protein/ HEK293 fibroblast cells	TRPA1 activation, Chemical covalent binding to sulfhydyl group on TRPA1 receptor protein/ H	1230	TRPV1 activation, TRPV1	TRPV1 activation, TRPV1	Molecular1231	Oxidization of biomolecules, Lipid bilayer and cellular proteins	Oxidization of biomolecules, Lipid bilayer and cellular proteins	1232	Production of nerve growth factor , 	Production of nerve growth factor ,	1233	Production, Nerve growth factor	Production, Nerve growth factor	1234	Production of nerve growth factor , Epithelial irritation	Production of nerve growth factor , Epithelial irritation	Tissue1235	Non-neuronal production of IL-8/CXCL1, Epithelial irritation	Non-neuronal production of IL-8/CXCL1, Epithelial irritation	Tissue1236	Generation of novel epitopes , Antigen presentation	Generation of novel epitopes , Antigen presentation	Cellular1237	Sensitization, Immune system	Sensitization, Immune system	Individual1238	Activation of oxidative stress pathway	Oxidation	Molecular1239	Altered, Gene Expression	Altered, Gene Expression	Molecular1240	Altered, Protein Production	Altered, Protein Production	Cellular1241	Increased, Motility	Increased, Motility	Cellular1242	Increased, Second Messenger Production	Increased, Second Messenger Production	Cellular1243	Altered, Ca2+-calmodulin activated signal transduction	Altered, Ca2+-calmodulin activated signal transduction	Cellular1244	Mucus hypersecretion, 	Mucus hypersecretion,	1245	Mucus , Hypersecretion	Mucus , Hypersecretion	1246	Lung function, Decrease	Lung function, Decrease	1247	EGFR , PPAR-alpha activation	EGFR , PPAR-alpha activation	1248	EGFR , Activation	EGFR , Activation	1249	Oxidative Stress, 	Oxidative Stress,	1250	Decrease, Lung function	Decrease, Lung function	Individual1251	Chronic, Mucus hypersecretion	Chronic, Mucus hypersecretion	Tissue1252	In-utero DNA topoisomerase II “poisons-	DNA topoisomerase II “poisons”	Molecular1253	In utero MLL chromosomal translocation	MLL translocation	Cellular1254	Infant leukaemia	IFL	Individual1255	induced spawning	induced spawning	Individual1256	increased mantel display	increased mantel display	Organ1257	Induced parturition	Induced parturition	Individual1258	Decompartmentalization	Decompartmentalization	Cellular1259	narcosis	narcosis	Cellular1260	Direct mitochondrial inhibition	Direct mitochondrial inhibition	Molecular1261	Mitochondrial impairment	Mitochondrial impairment	Molecular1262	Apoptosis	Apoptosis	Tissue1263	Necrosis	Necrosis	Tissue1264	Induction, Nuclear receptor E75b gene	Induction, E75b gene	Molecular1265	Suppression, Fushi tarazu factor-1 gene	Suppression, Ftz-f1 gene	Molecular1266	Reduction, Release of circulating crustacean cardioactive peptide	Reduction, Release of circulating CCAP	Tissue1267	Reduction, Ecdysis motoneuron bursts	Reduction, Ecdysis motoneuron bursts	Tissue1268	Reduction, Excitatory postsynaptic potential	Reduction, Excitatory postsynaptic potential	Tissue1269	Increase, COX-2 expression	Increase, COX-2 expression	Molecular1270	Inactivation of PPAR_	Inactivation of PPAR_	Molecular1271	Activation of TGF-_ signaling	Activation of TGF-_ signaling	Cellular1272	Differentiation of Myofibroblast	Differentiation of Myofibroblast	Cellular1273	Expression of Collagen	Expression of Collagen	Cellular1274	Production of _-smooth muscle actin	Production of _-smooth muscle actin	Cellular1275	Collagen Deposition	Collagen Deposition	Tissue1276	Lung fibrosis	Lung fibrosis	Organ1277	Reproductive failure	Reproductive failure	Individual1278	ROS formation	ROS formation	Molecular1279	Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK	Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK	Cellular1280	Activation, HIF-1	Activation, HIF-1	Cellular1281	Increased, DNA Damage-Repair	Increased, DNA Damage-Repair	Cellular1282	Activation, JAK/STAT pathway	Activation, JAK/STAT pathway	Cellular1283	Activation, TGF-beta pathway	Activation, TGF-beta pathway	Cellular1284	Up Regulation, SREBF2	Up Regulation, SREBF2	Cellular1285	Up Regulation, Unsaturated fatty acid	Up Regulation, Unsaturated fatty acid	Cellular1286	Down Regulation, GSS and GSTs gene	Down Regulation, GSS and GSTs gene	Cellular1287	Glutathione synthesis	Glutathione synthesis	Cellular1288	Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene	Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene	Cellular1289	Perturbation of cholesterol	Perturbation of cholesterol	Cellular1290	Glutathione homeostasis	Glutathione homeostasis	Cellular1291	Hepatotoxicity	Hepatotoxicity	Cellular1292	Activation, JNK	Activation, JNK	Cellular1293	Activation, FOXO	Activation, FOXO	Cellular1294	Inhibition, Wnt pathway	Inhibition, Wnt pathway	Cellular1295	Defect of Embryogenesis	Defect of Embryogenesis	Tissue1296	Increase, insulin	Increase, insulin	Molecular1297	Activation, insulin receptor 	Activation, insulin receptor	Molecular1298	Activation, mTORC2	Activation, mTORC2	Molecular1299	Activation, AKT	Activation, AKT	Molecular1300	Activation, mTORC1	Activation, mTORC1	Molecular1301	Activation, SREBP-1	Activation, SREBP-1	Molecular1302	Activation, L-FABP 	Activation, L-FABP	Molecular1303	Activation, HSD17B4	Activation, HSD17B4	Molecular1304	Activation, FXR	Activation, FXR	Molecular1305	Increase, cytosolic fatty acid	Increase, cytosolic fatty acid	Molecular1306	Increased, lipogenesis	Increased, lipogenesis	Molecular1307	Inhibition, LXR	Inhibition, LXR	Molecular1308	Inhibition, LRH-1	Inhibition, LRH-1	Molecular1309	Activation, aPKC	Activation, aPKC	Molecular1310	Activation, PI3K	Activation, PI3K	Molecular1311	Inhibition, Steatosis	Inhibition, Steatosis	Organ1312	Induction, fatty acid beta-oxidation	Induction, fatty acid beta-oxidation	Molecular1313	Decrease, cytosolic fatty acid	Decrease, cytosolic fatty acid	Molecular1314	Activation, LRH-1	Activation, LRH-1	Molecular1315	Increase, Selective Serotonin Reuptake Inhibitors (SSRIs)	Increase, SSRIs	Molecular1316	Inhibit, serotonin transporter activity	Inhibit, serotonin transporter activity	Molecular1317	Decreased, serotonin transporter activity	Decreased, serotonin transporter activity	Molecular1318	Decreased, extracellular sodium (Na+) 	Decreased, extracellular Na+	Molecular1319	Decreased, extracellular chloride (Cl-)	Decreased, extracellular chloride (Cl-)	Molecular1320	Increased, extracellular serotonin	Increased, extracellular serotonin	Molecular1321	Increased, intracellular sodium (Na+)	Increased, intracellular sodium (Na+)	Molecular1322	Increased, intracellular chloride (Cl-)	Increased, intracellular chloride (Cl-)	Molecular1323	Decreased, intracellular serotonin	Decreased, intracellular serotonin	Molecular1324	Decreased, packaged serotonin	Decreased, packaged serotonin	Molecular1325	Decreased, synaptic release	Decreased, synaptic release	Molecular1326	Increased, 5-HT3 (5-hydroxytryptamine)	Increased, 5-HT3	Molecular1327	Decreased, seizure	Decreased, seizure	Individual1328	Inactivated, 5-HTR (serotonin receptors)	Inactivated, 5-HTR	Molecular1329	Reduce expression, BDNF (Brain-derived neurotrophic factor)	Reduce expression, BDNF	Molecular1330	Decreased, neuroplasticity	Decreased, neuroplasticity	Molecular1331	Inhibit, agitation	Inhibit, agitation	Individual1332	Inhibit, depression	Inhibit, depression	Individual1333	Increase, mental stress	Increase, mental stress	Individual1334	Increase, cortisone	Increase, cortisone	Molecular1335	Reduced, BDNF (Brain-derived neurotrophic factor)	Reduced, BDNF	Molecular1336	Activation, 5-HT2A (Serotonin 2A)	Activation, 5-HT2A	Molecular1337	Activate, PLC (Phospholipase C)	Activate, PLC	Molecular1338	Increase, inositol triphosphate	Increase, inositol triphosphate	Molecular1339	Increase, intracellular calcium	Increase, intracellular calcium	Cellular1340	Activate, calmodulin	Activate, calmodulin	Molecular1341	Increase, myosin light chain phosphorylation	Increase, myosin light chain phosphorylation	Molecular1342	Increase, vascular smooth muscle contraction	Increase, vascular smooth muscle contraction	Molecular1343	Increase, hypertension	Increase, hypertension	Individual1344	Increased, seizure	Increased, seizure	Individual1345	Increased, agitation	Increased, agitation	Molecular1346	Increased, depression	Increased, depression	Individual1347	Decreased, extracellular serotonin	Decreased, extracellular serotonin	Molecular1348	Increase, seizure	Increase, seizure	Individual1349	Activated, presynaptic neuron 1	Activated, presynaptic neuron 1	Molecular1350	Increased, glutamate	Increased, glutamate	Molecular1351	Activated, NMDA receptor	Activated, NMDA receptor	Molecular1352	Activated, voltage-gated sodium channel	Activated, voltage-gated sodium channel	Molecular1353	Inhibit, voltage-gated sodium channel	Inhibit, voltage-gated sodium channel	Molecular1354	Treat, carbamazepine	Treat, carbamazepine	Molecular1355	Activated, membrane depolarization	Activated, membrane depolarization	Cellular1356	Inactive, membrane depolarization	Inactive, membrane depolarization	Molecular1357	Increased, RDX dose	Increased, RDX dose	Molecular1358	Repress, GABA-A receptor	Repress, GABA-A receptor	Molecular1359	Activate, GABA-A receptor	Activate, GABA-A receptor	Molecular1360	Activate, presynaptic neuron 2	Activate, presynaptic neuron 2	Molecular1361	Increase, GABA	Increase, GABA	Molecular1362	Increased, hippocampal hyperdepolarization	Increased, hippocampal hyperdepolarization	Molecular1363	Increased, epilepsy	Increased, epilepsy	Individual1364	Increase, Excessive reactive oxygen species generation	Increase, Excessive ROS generation	Molecular1365	Increase, Apoptosis	Increase, Apoptosis	Cellular1366	Decrease, Oogenesis	Decrease, Oogenesis	Cellular1367	Inhibit, gastric ulcer formation	Inhibit, gastric ulcer formation	Organ1368	Inhibition, PTGS-1 (Prostaglandin-endoperoxide synthase 1)	Inhibition, PTGS-1	Molecular1369	Activation, PTGS-1 (Prostaglandin-endoperoxide synthase 1)	Activation, PTGS-1	Molecular1370	Activation, PTGS-2 (Prostaglandin-endoperoxide synthase 2)	Activation, PTGS-2	Molecular1371	Inhibition, PTGS-2 (Prostaglandin-endoperoxide synthase 2)	Inhibition, PTGS-2 (Prostaglandin-endoperoxide synthase 2)	Molecular1372	Increase, bicarbonate 	Increase, bicarbonate	Molecular1373	Increase, mucous	Increase, mucous	Molecular1374	Increase, mucosal blood flow	Increase, mucosal blood flow	Tissue1375	Increase, platelet aggregation	Increase, platelet aggregation	Tissue1376	Increase, angiogenesis	Increase, angiogenesis	Tissue1377	Decrease, leukocyte adherence	Decrease, leukocyte adherence	Tissue1378	Increase, leukocyte adherence	Increase, leukocyte adherence	Tissue1379	Activate, leukocyte 	Activate, leukocyte	Cellular1380	Activate, mucosal defense	Activate, mucosal defense	Tissue1381	Increase, surfactant	Increase, surfactant	Molecular1382	Decrease, surfactant	Decrease, surfactant	Molecular1383	Activate, phospholipase	Activate, phospholipase	Molecular1384	Increase, ammonium (NH4+)	Increase, ammonium (NH4+)	Molecular1385	Activated, gastric ulcer formation	Activated, gastric ulcer formation	Organ1386	CYP7B activity, inhibition	CYP7B activity, inhibition	Molecular1387	7_-hydroxypregnenolone synthesis in the brain, decreased	7_-hydroxypregnenolone synthesis in the brain, decreased	Cellular1388	Dopamine release in the brain, decreased	Dopamine release in the brain, decreased	Tissue1389	Locomotor activity, decreased	Locomotor activity, decreased	Individual1390	Sexual behavior, decreased	Sexual behavior, decreased	Individual1391	Activation of Cyp2E1 in the liver	Activation of Cyp2E1 in the liver	Molecular1392	Oxidative Stress 	Oxidative Stress	Molecular1393	Hepatocytotoxicity	Hepatocytotoxicity	Cellular1394	Hepatocellular Regenerative Proliferation 	Hepatocellular Regenerative Proliferation	Cellular1395	Liver Cancer	Liver Cancer	Organ1396	Increased, glucocorticoid receptor activity	Increased, glucocorticoid receptor activity	Molecular1397	Increased, serotonin transporter activity	Increased, serotonin transporter activity	Cellular1398	Increased, intracellular serotonin	Increased, intracellular serotonin	Cellular1399	Increased, packaged serotonin	Increased, packaged serotonin	Cellular1400	Increased, synaptic release	Increased, synaptic release	Cellular1401	Decreased, 5-HT3	Decreased, 5-HT3	Tissue1402	Reduced, PTGS1 function	Reduced, PTGS1 function	Molecular1403	Reduced, platelet aggregation	Reduced, platelet aggregation	Tissue1404	Decreased, mucosal blood flow	Decreased, mucosal blood flow	Tissue1405	Reduced, mucosal defense	Reduced, mucosal defense	Tissue1406	Decreased, mucous	Decreased, mucous	Tissue1407	Decreased, bicarbonate	Decreased, bicarbonate	Tissue1408	Reduced, PTGS2 function	Reduced, PTGS2 function	Cellular1409	Decreased, angiogenesis	Decreased, angiogenesis	Tissue1410	Increased, leukocyte adherence	Increased, leukocyte adherence	Tissue1411	Increased, leukocyte activation	Increased, leukocyte activation	Tissue1412	Helicobacter pylori infection	Helicobacter pylori infection	Tissue1413	Reduced, presynaptic neuron 2 activity	Reduced, presynaptic neuron 2 activity	Cellular1414	Decreased, GABA	Decreased, GABA	Cellular1415	Reduced, GABA-A receptor activation	Reduced, GABA-A receptor activation	Molecular1416	Decreased, intracellular chloride	Decreased, intracellular chloride	Cellular1417	NFE2/Nrf2 repression	NFE2/Nrf2 repression	Molecular1418	Increased, steatosis	Increased, steatosis	Organ1419	Reduced, FXR activity	Reduced, FXR activity	Molecular1420	Reduced, SHP activity	Reduced, SHP activity	Molecular1421	Activated, LXR	Activated, LXR	Molecular1422	Reduced, PPARalpha	Reduced, PPARalpha	Molecular1423	Reduced, HSD17B4 activity	Reduced, HSD17B4 activity	Molecular1424	Reduced, fatty acid beta oxidation	Reduced, fatty acid beta oxidation	Molecular1425	Mu Opioid Receptor Agonism	Mu Opioid Receptor Agonism	Molecular1426	Release of G Proteins	Release of G Proteins	Cellular1427	Opening of G protein gated inward rectifying K channels	Opening of GIRK channels	Cellular1428	Analgesia	Analgesia	Individual1429	Inhibition of N-type Ca ion channels	Inhibition of Ca Channels	Cellular1430	Inhibition of neurotransmitter vesicle release	Inhibition of neurotransmitter release	Cellular1431	Serotonin 1A Receptor Agonism	Serotonin 1A Receptor Agonism	Molecular1432	Anti-depressant Activity	Anti-depressant Activity	Individual1433	Increased CGRP, neuronal release of CGRP	Increased CGRP	Cellular1434	Irritation of nasal mucosa inducing sneeze reflex	Irritation induced sneezing	Tissue1435	Increased neurokinin A (NKA) by neuronal cells	Increased NKA	Cellular1436	neurogenic inflammation of sensory nerves	neurogenic inflammation	Cellular1437	Sensing of the stressor by pulmonary cells	Sensing of the stressor	Molecular1438	Increased production of pulmonary, pro-inflammatory cytokines	Pro-inflammatory cytokines increased	Molecular1439	Increased production of pulmonary SAA	SAA production increased	Molecular1440	Formation of HDL-SAA	HDL-SAA formation	Cellular1441	Increased systemic total cholesterol pool	Systemic cholesterol increased	Organ1442	Foam cell formation	Foam cell formation	Organ1443	Plaque progression in arteries	Plaque progression	Individual1444	Increase, Follicular atresia	Increase, Follicular atresia	Tissue1445	Increase, Lipid peroxidation	Increase, Lipid peroxidation	Cellular1446	Increase, Uncoupling of oxidative phosphorylation	Increase, Uncoupling of OXPHOS	Cellular1447	obesity	obesity	Individual1448	activation of CCAAT/enhancer-binding protein alpha	activation of CEBPA	Molecular1449	increased adipogenesis	increased adipogenesis	Tissue1450	decreased dopamine	decreased dopamine	Molecular1451	decreased reward	decreased reward	Individual1452	decreased DNA methylation of tyrosine hydroxylase	decreased DNA methylation of tyrosine hydroxylase	Cellular1453	decreased methylation of dopamine transporter promoter	decreased methylation of dopamine transporter promoter	Cellular1454	chronic high fat diet	chronic high fat diet	Individual1455	Incudtion, Sustained inflammatory cytokine release	Sustained inflammatory cytokine release	Molecular1456	Increase, Differentiation of fibroblasts	Differentiation of fibroblasts	Cellular1457	Induction, Epithelial Mesenchymal Transition	EMT	Cellular1458	Pulmonary fibrosis	Pulmonary fibrosis	Organ1459	Induction, Cell damage sensing	Cell damage sensing	Molecular1460	Increased Substance P (SP) by goblet cells	SP release	Cellular1461	DNA double-strand break 	DSB	Molecular1462	Thiol group of chemicals interact with sulfuhydryl groups of proteins to form thiol adducts	Thiol protein adducts	Molecular1463	Inhibition of lysyl oxidase	Inhibition of lysyl oxidase	Cellular1464	Reduction of collagen crosslinking	Reduction of collagen crosslinking	Tissue1465	Weak collagen matrix	Weak collagen matrix	Tissue1466	Notochord distortion or malformations	Notochord malformation	Organ1467	Growth, reduction	Growth, reduction	Individual1468	Activation, Latent Transforming Growth Factor Beta 1	TGFbeta1 activation	Molecular1469	Activation, Transforming Growth Factor beta pathway	TGFbeta pathway activation	Molecular1470	inherited mutations in offspring	increase in inherited mutations	Individual			Help			About			FAQ			Metrics 			